Guggenheim Initiates Coverage On Spruce Biosciences with Buy Rating, Announces Price Target of $123
Benzinga Newsdesk 4 months ago
NewsPrice TargetInitiationAnalyst Ratings
Guggenheim analyst Debjit Chattopadhyay initiates coverage on Spruce Biosciences (NASDAQ:SPRB) with a Buy rating and announces Price Target of $123.
Guggenheim analyst Debjit Chattopadhyay initiates coverage on Spruce Biosciences (NASDAQ:SPRB) with a Buy rating and announces Price Target of $123.